Sociedad Americana de Hirudoterapia

Metagenomic analysis of the medicinal leech gut microbiota

Basic science published in Front Microbiol (2014)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportGenómica y proteómicaSeguridad y control de infeccionesMaltz MA et al. · Frontiers in microbiology, 2014

Abstract

There are trillions of microbes found throughout the human body and they exceed the number of eukaryotic cells by 10-fold. Metagenomic studies have revealed that the majority of these microbes are found within the gut, playing an important role in the host's digestion and nutrition. The complexity of the animal digestive tract, unculturable microbes, and the lack of genetic tools for most culturable microbes make it challenging to explore the nature of these microbial interactions within this niche. The medicinal leech, Hirudo verbana, has been shown to be a useful tool in overcoming these challenges, due to the simplicity of the microbiome and the availability of genetic tools for one of the two dominant gut symbionts, Aeromonas veronii. In this study, we utilize 16S rRNA gene pyrosequencing to further explore the microbial composition of the leech digestive tract, confirming the dominance of two taxa, the Rikenella-like bacterium and A. veronii. The deep sequencing approach revealed the presence of additional members of the microbial community that suggests the presence of a moderately complex microbial community with a richness of 36 taxa. The presence of a Proteus strain as a newly identified resident in the leech crop was confirmed using fluorescence in situ hybridization (FISH). The metagenome of this community was also pyrosequenced and the contigs were binned into the following taxonomic groups: Rikenella-like (3.1 MB), Aeromonas (4.5 MB), Proteus (2.9 MB), Clostridium (1.8 MB), Eryspelothrix (0.96 MB), Desulfovibrio (0.14 MB), and Fusobacterium (0.27 MB). Functional analyses on the leech gut symbionts were explored using the metagenomic data and MG-RAST. A comparison of the COG and KEGG categories of the leech gut metagenome to that of other animal digestive-tract microbiomes revealed that the leech digestive tract had a similar metabolic potential to the human digestive tract, supporting the usefulness of this system as a model for studying digestive-tract microbiomes. This study lays the foundation for more detailed metatranscriptomic studies and the investigation of symbiont population dynamics.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Resumen

16S rRNA pyrosequencing of Hirudo verbana gut reveals dominance of Rikenella-like and Aeromonas with 36-taxa richness.

Por qué esto importa para la hirudoterapia

Este estudio utilizó pirosecuenciación del gen 16S rRNA y análisis metagenómico para caracterizar la microbiota intestinal de la sanguijuela medicinal Hirudo verbana, confirmando dos taxones dominantes (una bacteria tipo Rikenella y Aeromonas veronii) e identificando 36 taxones en total, incluido un residente del género Proteus recién confirmado. El metagenoma del tracto digestivo de la sanguijuela mostró un potencial metabólico similar al del tracto digestivo humano, respaldando a la sanguijuela como modelo para el estudio de microbiomas del tracto digestivo. Para ASH, esto proporciona conocimiento fundamental sobre la biología simbiótica de las sanguijuelas medicinales, aunque su relevancia es indirecta ya que no aborda el secretoma de la sanguijuela ni las aplicaciones de la hirudoterapia. Salvedad: se trata de un estudio básico de microbiología y ecología sin hallazgos clínicos o terapéuticos directos.

Citación

Metagenomic analysis of the medicinal leech gut microbiota.

Maltz MA et al. · Frontiers in microbiology, 2014

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.